Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.

Item
http://www.wikidata.org/entity/Q30980654
Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girlsQuadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial.Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study.Current status and future prospects for human papillomavirus vaccines.Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals.Use of a 2-Dose Schedule for Human Papillomavirus Vaccination-Updated Recommendations of the Advisory Committee on Immunization Practices.Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
P2860

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.

Item
http://www.wikidata.org/entity/Q30980654
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Sustained immunogenicity of th ...... tions from a randomized study.
@ast
Sustained immunogenicity of th ...... tions from a randomized study.
@en
type
label
Sustained immunogenicity of th ...... tions from a randomized study.
@ast
Sustained immunogenicity of th ...... tions from a randomized study.
@en
prefLabel
Sustained immunogenicity of th ...... tions from a randomized study.
@ast
Sustained immunogenicity of th ...... tions from a randomized study.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Sustained immunogenicity of th ...... tions from a randomized study.
@en
P2093
P2860
P304
P31
P356
10.1080/21645515.2015.1065363
P433
P478
P50
P577
P698
P921
P932